Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5. Background: Historically, symptoms of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback